DOCSLIB.ORG

Hexachlorophenum Hexaminolaevulinas Hydrochloridum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hexachlorophenum Hexaminolaevulinas Hydrochloridum 29 Hexachlorophenum Heksaklorofeeni Hexaklorofen Hexachlorophene Hexaminolaevulinas Heksaminolevulinaattihyd- Hexaminolevulinathydro- Hexaminolevulinate hyd- hydrochloridum rokloridi klorid rochloride Hexapropymatum Heksapropymaatti Hexapropymat Hexapropymate Hexobarbitalum Heksobarbitaali Hexobarbital Hexobarbital Hexocyclium Heksosyklium Hexocyklium Hexocyclium Hexoprenalinum Heksoprenaliini Hexoprenalin Hexoprenaline Hexylnicotinatum Heksyylinikotinaatti Hexylnikotinat Hexyl nicotinate Hexylresorcinolum Heksyyliresorsinoli Hexyh-esorcinol Hexylresorcinol Hirudinum Hirudiini Hirudin Hirudin Histamini Histamiinidihydrokloridi Histamindihydroklorid Histamine dihydrochloride dihydrochloridum Histaminum Histamiini Histamin Histamine Histapyrrodinum Histapyrrodiini Histapyrrodin Histapyrrodine Hisb-elinum Histreliini Histrelin Histrelin Homatropini Homati'opiinimetyyli- Homatropinmetylbromid Homatropine methylbromidum bromidi methylbromide Homatropinum Homatropiini Homatropin Homatropine Hormonum parathyroidum Paratyroidihormoni Parathormon Parathyroid hormone (rdna) (rdna) Hyaluronidasum Hyaluronidaasi Hyaluronidas Hyaluronidase Hydralazinum Hydralatsiini Hydralazin Hydralazine Hydrochlorothiazidum Hydroklooritiatsidi Hydroklortiazid Hydrochlorothiazide Hydrocodonum Hydrokodoni Hydrokodon Hydrocodone Hydrocortisonum Hydrokortisoni Hydrokortison Hydrocortisone Hydroflumethiazidum Hydroflumetiatsidi Hydroflumetiazid Hydroflumethiazide Hydromorphonum Hydromorfoni Hydromorfon Hydromorphone Hydrotalcitum Hydrotalsiitti Hydrotalcit Hydrotalcite Hydroxyaethyli salicylas Hydroksietyylisalisylaatti Hydroxietylsalicylat Hydroxyethyl salicylate Hydroxyamfetaminum Hydroksiamfetamiini Hydroxiamfetamin Hydroxyamfetamine Hydroxycarbamidum Hydroksikarbamidi Hydroxikarbamid Hydroxycarbamide Hydroxychloroquinum Hydroksiklorokiini Hydroxiklorokin Hydroxychloroquine Hydroxycobalaminum Hydroksikobalamiini Hydroxikobalamin Hydroxocobalamin Hydroxyprogesteronum Hydroksiprogesteroni Hydroxiprogesteron Hydroxyprogesterone Hydroxytryptophanum Hydroksitryptofaani Hydroxitryptofan Hydroxytryptophan (5-HTP) Hydroxyzinum Hydroksitsiini Hydroxizin Hydroxyzine Hyoscyaminum Hyoskyamiini Hyoscyamin Hyoscyamine Hypromellosum Hypromelloosi Hypromellos Hypromellose Ibafloxacinum Ibafloksasiini Ibafloxacin Ibafloxacin Ibopamini hydrochloridum Ibopamiinihydrokloridi Ibopaminhydroklorid Ibopamine hydrochloride Ibritumomabum Ibritumomabitiuksetaani Ibritumomabtiuxetan Ibritumomab tiuxetan tmxetanum Ibuprofenum Ibuprofeeni Ibuprofen Ibuprofen Ibutilidum Ibutilidi Ibutilid Ibutilide Icatibantum Ikatibantti Icatibant Icatibant Ichthammolum Iktammoli Iktammol Ichthammol 30 Icodextrinum Ikodekstriini Ikodextrin Icodextrin Idarubicini Idarubisiinihydrokloridi Idarubicinhydroklorid Idarubicin hydrochloride hydrochloridum Idebenonum Idebenoni Idebenon Idebenone Idoxuridinum Idoksuridiini Idoxuridin Idoxuridine Idursulfasum Idursulfaasi Idursulfas Idursulfase Ifosfamidum Ifosfamidi Ifosfamid Ifosfamide Igovomabum Igovomabi Igovomab Igovomab Iloprostum Iloprosti Iloprost Iloprost Imatinibum Imatinibi Imatinib Imatinib Imidaclopridum Imidaklopridi Imidacloprid Imidacloprid Imidaprili hydrochloridum Imidapriilihydrokloridi Imidaprilhydroklorid Imidapril hydrochloride Imiglucerasum Imiglukeraasi Imiglukeras Imiglucerase Imipenemum Imipeneemi Imipenem Imipenem Imipramini oxidum Imipramiinioksidi Imipraminoxid Imipramine oxide Imipraminum Imipramiini Imipramin Imipramine Imiquimodum Imikimodi Imikimod Imiquimod Immunoglobulinum Immunoglobuliini Immunoglobulin Immunoglobulm Indacaterolum maleatum Indakaterolimaleaatti Indakaterol maleat Indacaterol maleate Indapamidum Indapamidi Indapamid Indapamide Indinavirum Indinaviiri Indinavir Indinavir Indometacinum Indometasiini Indometacin Indometacin Indoraminum Indoramiini Indoramm Indoramin Indoxacarbum Indoksakarbi Indoxakarb Indoxacarb Infliximabum Infliksimabi Infliximab Infliximab Inositoli nicotinas Inositolinikotinaatti Inositolnikotinat Inositol nicotinate Inositolum Inositoli Inositol Inositol Insulinum Insuliini Insulin Insulin Insulinum aspartatum Aspartinsuliini Insulin aspart Insulin aspart Insulinum detemirum Detemirinsuliini Insulin detemir Insulin detemir Insulinum glarginum Glargininsuliini Insulin glargin Insulin glargine Insulinum glulisinum Glulisinsuliini Insulin glulisin Insulin glulisine Insulinum humanum Insuliini, ihmisen Insulin, humant Insulin, human Insulinum lisprum Lisproinsuliini Insulin lispro Insulin lispro Interferonum Interferoni Interferon Interferon Interferonum alfa Interferoni alfa luonnolli- Interferon alfa naturiig Interferon alfa nen Interferonum beta-la Interferonibeeta-1 a Interferon-beta-1 a Interferonbeta-la Interferonum beta-Ib Interferonibeeta-1 b Interferon-beta-1 b Interferon beta-lb lobenguani ["'I] Jobenguani["'I] Jobenguan[I3II] lobenguane [I] lobitridolum Jobitridoli Jobitridol lobitridol lodamidum Jodiamidi Jodamid lodamide lodixanolum Jodiksanoli Jodixanol lodixanol lodomethylnorcholestero- Jodmetylnorkolesterol lodomethylnorcholesterol him [131I] \mn [131I] [131I] lodoquindum Jodokindi Jodokvind lodoquind 31 lofendylatum Jofendylaatti Jofendylat lofendylate loflupanum ['"I] Joflupaani ['"I] loflupan ["•'I] loflupane ["'!] lohexolum Joheksoli Johexol lohexol lolopridum ['"I] Jolopridi ['"I] loloprid ["-'I] lolopride ['"I] lomeprolum Jomeproli Jomeprol lomeprol lopamidolum Jopamidoli Jopamidol lopamidol lopentolum Jopentoli Jopentol lopentol lopromidum Jopromidi Jopromid lopromide lopydolum Jopydoli Jopydol lopydol lotrolanum Jotrolaani Jotrolan lotrolan loversolum Joversoli Joversol loversol Ipilimumabum Ibilimumabi Ibilimumab Ibilimumab Ipratropii bromidum Ipratropiinibromidi Ipratropiumbromid Ipratropium bromide Iprazochromum Ipratsokromi Iprazokrom Iprazochi-ome Iprindolum Iprindoli Iprindol Iprindole Irbesartanum Irbesartaani Irbesartan Irbesartan Irinotecani Irinotekaanihydrokloridi Irinotekanhydroklorid Irinotecan hydrochloride hydrochloridum Isoaminilum Isoaminiili Isoaminil Isoaminile Isocarboxazidum Isokarboksatsidi Isokarboxazid Isocarboxazid Isoconazolum Isokonatsoli Isokonazol Isoconazole Isoetarinum Isoetariini Isoetarin Isoetarine Isoflupredonum Isoflupredoni Isoflupredon Isoflupredone Isofluranum Isofluraani Isofluran Isoflurane Isoniazidum Isoniatsidi Isoniazid Isoniazid Isoprenalinum Isoprenaliini Isoprenalin Isoprenalme Isopropamidi bromidum Isopropamidibromidi Isopropamidbromid Isopropamide bromide Isopropamidum Isopropamidi Isopropamid Isopropamide Isopropyli nicotinas Isopropyylinikotinaatti Isopropyhiikotinat Isopropyl nicotinate Isosorbidi dinitras Isosorbididinitraatti Isosorbiddinitrat Isosorbide dinitrate Isosorbidi mononitras Isosorbidimononitraatti Isosorbidmononitrat Isosorbide mononitrate Isothipendylum Isotipendyyli Isotipendyl Isothipendyl Isotretinoinum Isotretinoiini Isotretinoin Isotretinoin Isoxicamum Isoksikaami Isoxikam Isoxicam Isoxsuprinum Isoksupriini Isoxupria Isoxsuprine Isradipinum Isradipiini Isradipin Isradipine Itraconazolum Itrakonatsoli Itrakonazol Itraconazole Itramini tosilas Itramiinitosilaatti Itramintosilat Itramin tosilate Ivabradinum Ivabradiini Ivabradin Ivabradine Ivermectinum Ivermektiini Ivermektin Ivermectin Ixabepilonum Iksabepiloni Ixabepilon Ixabepilone Kalii bromidum Kaliumbromidi Kaliumbromid Potassium bromide Kalii cam'enoas Kaliumkanrenoaatti Kaliumkanrenoat Potassium canrenoate Kalii clavulanas Kaliumklavulanaatti Kaliumklavulanat Potassium clavulanate Kalii clorazepas Kaliumkloratsepaatti Klaiumklorazepat Potassium clorazepate Kalii iodidum Kaliumjodidi Kaliumjodid Potassium iodide 32 Kalii salicylas Kaliumsalisylaatti Kaliumsalicylat Potassium salicylate Kalii sulfoguajacolas Kaliumsulfoguajakolaatti Kaliumsulfoguajakolat Potassium guaiacolsulfate Kallidinogenasum Kallidinogenaasi Kallidinogenas Kallidinogenase Kanamycmum Kanamysiini Kanamycin Kanamycin Ketaminum Ketamiini Ketamin Ketamine Ketanserinum Ketanseriini Ketanserm Ketanserin Ketazolamum Ketatsolaami Ketazolam Ketazolam Ketoconazolum Ketokonatsoli Ketokonazol Ketoconazole Ketoprofenum Ketoprofeeni Ketoprofen Ketoprofen Ketorolacum Ketorolaakkitrometamoli Ketorolaktrometamol Ketorolac trometamol trometamolum Ketotifenum Ketotifeeni Ketotifen Ketotifen Labetalolum Labetaloli Labetalol Labetalol Lacidipinum Lasidipiini Lacidipin Lacidipine Lacosamidum Lakosamidi Lacosamide Lacosamide Lactitolum monohydricum Laktitolimonohydraatti Laktitolmonohydrat Lactitol monohydrate Lactulosum Laktuloosi Laktulos Lactulose Lamivudinum Lamivudiini Lamivudin Lamivudine Lamotriginum Lamotrigiini Lamotrigin Lamotrigme Lanatosidum C Lanatosidi C Lanatosid C Lanatoside C Lanreotidum Lanreotidi Lanreotid Lanreotide Lansoprazolum Lansopratsoli Lansoprazol Lansoprazole Lanthani carbonas Lantaanikarbonaatti Lantaakarbonat Lanthanum carbonate Lapatinibi tosilas Lapatmibiditosilaatti- Lapatinibditosilatmono- Lapatinib ditosilate mono- monohydricus monohyd-raatti hydrat hydrate Lapatinibum Lapatinibi Lapatinib Lapatinib Laronidasum Laronidaasi Laronidas Laronidase Laropiprantum Laropiprantti Laropiprant Laropiprant Lasofoxifenum Lasofoksifeeni Lasofoxifen Lasofoxifene L-Asparaginasum L-Asparaginaasi L-Asparaginas L-Asparaginase Latamoxefum dinatricum Latamoksefidinatrium Latamoxefdinatrium Latamoxef disodium Latanoprostum Latanoprosti Latanoprost Latanoprost Lecirelinum Lesireliini Lecirelin Lecirelin Leflunomidum Leflunomidi Leflunomid Leflunomide Lenalidomidum Lenalidomidi Lenalidomid Lenalidomide Lenograstimum Lenograstiimi Lenograstim Lenograstim Lepirudinum Lepirudiini Lepirudin
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • The Effects of Osaterone Acetate on Clinical Signs and Prostate Volume in Dogs with Benign Prostatic Hyperplasia
    Polish Journal of Veterinary Sciences Vol. 21, No. 4 (2018), 797–802 DOI 10.24425/pjvs.2018.125601 Original article The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia P. Socha, S. Zduńczyk, D. Tobolski, T. Janowski Department of Animal Reproduction with Clinic, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 14, 10-719 Olsztyn, Poland Abstract A clinical trial was performed to evaluate the therapeutic efficacy of osaterone acetate (OSA) in the treatment of benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate (Ypozane, Virbac) was administered orally at a dose of 0.25 mg/kg body weight once a day for seven days to 23 dogs with BPH. During the 28-day trial, the dogs were monitored five times for their clinical signs and prostate volume. The OSA treatment promoted rapid reduction of clinical scores to 73.2% on day 7 and to 5.9% on day 28 (p<0.05). Osaterone acetate induced the complete clinical remission in approximately 83.0% of the dogs on day 28. The prostate volume regressed to 64.3% of the pretreatment volume after two weeks of the treatment (p<0.05) and to 54.7% at the end of the trial (p<0.05). In conclusion, OSA quickly reduced clinical signs and volume of the prostate glands in dogs with BPH. Key words: dogs, benign prostatic hyperplasia, osaterone acetate, prostate volume Introduction hyperplasia and subsequently transforms to cystic hyperplasia with the formation of multiple small cysts Benign prostatic hyperplasia (BPH) is the most within the prostatic parenchyma.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen Et Al
    USOO9005660B2 (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen et al. (45) Date of Patent: Apr. 14, 2015 (54) IMMEDIATE RELEASE COMPOSITION 4,873,080 A 10, 1989 Bricklet al. RESISTANT TO ABUSEBY INTAKE OF 4,892,742 A 1, 1990 Shah 4,898,733. A 2f1990 DePrince et al. ALCOHOL 5,019,396 A 5/1991 Ayer et al. 5,068,112 A 11/1991 Samejima et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 5,082,655 A 1/1992 Snipes et al. Jan Martin Oevergaard, Frederikssund 5,102,668 A 4, 1992 Eichel et al. 5,213,808 A 5/1993 Bar Shalom et al. (DK); Joakim Oestman, Lomma (SE) 5,266,331 A 11/1993 Oshlack et al. 5,281,420 A 1/1994 Kelmet al. (73) Assignee: Egalet Ltd., London (GB) 5,352.455 A 10, 1994 Robertson 5,411,745 A 5/1995 Oshlack et al. (*) Notice: Subject to any disclaimer, the term of this 5,419,917 A 5/1995 Chen et al. patent is extended or adjusted under 35 5,422,123 A 6/1995 Conte et al. U.S.C. 154(b) by 473 days. 5,460,826 A 10, 1995 Merrill et al. 5,478,577 A 12/1995 Sackler et al. 5,508,042 A 4/1996 OShlack et al. (21) Appl. No.: 12/701.248 5,520,931 A 5/1996 Persson et al. 5,529,787 A 6/1996 Merrill et al. (22) Filed: Feb. 5, 2010 5,549,912 A 8, 1996 OShlack et al.
    [Show full text]
  • 207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1
    207/2015 3 LÄÄKELUETTELON AINEET, LIITE 1. ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Dichlorbenzyl- 2,4-Diklooribentsyyli- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcoholum alkoholi alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- ami- 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol nophenolum Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini
    [Show full text]
  • NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (Nsaids)
    NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) A. Description Interfere with prostaglandin synthesis Alleviate inflammation and subsequent discomfort of rheumatoid conditions (GA) Available in oral and parenteral (IM) preparations CYCLOOXYGENASE INHIBITORS : are preferred because it does not decrease the cytoprotective lining of the stomach. Celebrex (Celecoxib) Vioxx (Rofecoxib)(No longer on market as of September 2004) Bextra (Valdecoxib)(No longer on market as of April 2005) There are also other COX-2 Inhibitors being developed, including: Prexige Lumiracoxib) Arcoxia (Etoricoxib) B. Examples Diclofenac (Voltaren) Etodolac (Lodine) Ibuprofen (Motrin) Naproxen (Naprosyn) Salicylates (ASA) COX-2 SELECTIVE INHIBITORS are the newest of the NSAIDs KETOROLAC is the only NSAID that can be administered by injection (intramuscularly or intravenously) and is indicated for the short-term use of severe to moderate pain. C. Major Side Effects GI irritation (local effect) Skin rash (hypersensitivity) Blood dyscrasias (decreased RBCs, WBCs, platelet synthesis) CNS and GU disturbances D. Nursing Care Administer with meals to reduce GI irritation Monitor blood work Assess vital signs Instruct client to report the occurrence of any side effects to the physician Encourage diet rich in nutrient-dense foods such as fruits, vegetables, whole grains, and legumes to improve and maintain nutritional status and prevent possible drug-induced nutrient deficiencies ANTIGOUT AGENTS (Uricosuric agent) A. Description Act by decreasing uric acid
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0302163 A1 Sanchez Et Al
    US 20140302163A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0302163 A1 Sanchez et al. (43) Pub. Date: Oct. 9, 2014 (54) WATER WITH IMPROVED TRANSDERMAL A613 L/714 (2006.01) AND CELLULAR DELIVERY PROPERTIES A 6LX3/59 (2006.01) AND METHODS OF MANUFACTURE AND A 6LX3/593 (2006.01) USE THEREOF A2.3L 2/52 (2006.01) A63/94 (2006.01) (71) Applicant: Subtech Industries, LLC, Stuart, FL (52) U.S. Cl. (US) CPC. A23L I/293 (2013.01); A23L 2/52 (2013.01); C02F I/30 (2013.01); A61 K33/00 (2013.01); (72) Inventors: David Sanchez, Port Saint Lucie, FL A6 IK3I/194 (2013.01); A61 K3I/714 (US); Len Deweerdt, Port Saint Lucie, (2013.01); A61 K3I/519 (2013.01); A61 K FL (US) 31/593 (2013.01); A61K 36/02 (2013.01) USPC ................. 424/600; 426/2: 426/66; 210/251: (73) Assignee: Subtech Industries, LLC, Stuart, FL 210/198.1; 210/201; 210/202: 514/569; 514/52: (US) 424/195.17; 514/789 (21) Appl. No.: 14/214,945 (57) ABSTRACT 1-1. A process for preparing conventional water sources for pro (22) Filed: Mar 16, 2014 viding “ideal state' cellular wellness benefits via topical Related U.S. Application Data hydrationabsorption. and The natural invention’s transdermal, process considersepithelial preconditioned O epicellular (60) Provisional application No. 61/788,206, filed on Mar. water sources that have removed solids, dissolved solids, 15, 2013. contaminants—both organic and inorganic and Subsequently the method purifies the water respective of removing patho Publication Classification gens, and structures the water for cellular uptake in the form of vicinal grade water, with improved characteristics of ideal (51) Int.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • 3258 N:O 1179
    3258 N:o 1179 LIITE 1 BILAGA 1 LÄÄKELUETTELON AINEET ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN Latinankielinen nimi Suomenkielinen nimi Ruotsinkielinen nimi Englanninkielinen nimi Latinskt namn Finskt namn Svenskt namn Engelskt namn Abacavirum Abakaviiri Abakavir Abacavir Abciximabum Absiksimabi Absiximab Abciximab Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoninatrium Acediasulfonnatrium Acediasulfone sodium Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini Acetfenolisatin Acetphenolisatin Acetylcholini chloridum Asetyylikoliinikloridi Acetylkolinklorid Acetylcholine chloride Acetylcholinum Asetyylikoliini Acetylkolin Acetylcholini Acetylcysteinum Asetyylikysteiini Acetylcystein Acetylcysteine Acetyldigitoxinum Asetyylidigitoksiini Acetyldigitoxin Acetyldigitoxin Acetyldigoxinum Asetyylidigoksiini Acetyldigoxin Acetyldigoxin Acetylisovaleryltylosini Asetyyli-isovaleryyli- Acetylisovaleryl- Acetylisovaleryltylosine tartras tylosiinitartraatti tylosintartrat tartrate Aciclovirum Asikloviiri Aciklovir Aciclovir Acidum acetylsalicylicum Asetyylisalisyylihappo Acetylsalicylsyra Acetylsalicylic acid Acidum alendronicum
    [Show full text]